Talbot Financial LLC Increases Stock Position in Novo Nordisk A/S $NVO

Talbot Financial LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 22.7% in the second quarter, Holdings Channel.com reports. The fund owned 124,973 shares of the company’s stock after purchasing an additional 23,133 shares during the period. Talbot Financial LLC’s holdings in Novo Nordisk A/S were worth $8,626,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Clarius Group LLC lifted its holdings in shares of Novo Nordisk A/S by 12.7% during the second quarter. Clarius Group LLC now owns 14,970 shares of the company’s stock valued at $1,033,000 after purchasing an additional 1,689 shares in the last quarter. Signature Wealth Management Partners LLC bought a new position in shares of Novo Nordisk A/S during the second quarter valued at $207,000. Bank Hapoalim BM lifted its holdings in shares of Novo Nordisk A/S by 23.1% during the second quarter. Bank Hapoalim BM now owns 27,750 shares of the company’s stock valued at $1,915,000 after purchasing an additional 5,215 shares in the last quarter. Impact Investors Inc lifted its holdings in shares of Novo Nordisk A/S by 63.7% during the second quarter. Impact Investors Inc now owns 9,327 shares of the company’s stock valued at $644,000 after purchasing an additional 3,629 shares in the last quarter. Finally, Ameriflex Group Inc. lifted its holdings in shares of Novo Nordisk A/S by 8.8% during the second quarter. Ameriflex Group Inc. now owns 6,511 shares of the company’s stock valued at $441,000 after purchasing an additional 525 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 1.6%

Shares of Novo Nordisk A/S stock opened at $59.68 on Friday. The company’s fifty day simple moving average is $54.92 and its 200-day simple moving average is $63.73. The stock has a market capitalization of $266.45 billion, a PE ratio of 16.39, a P/E/G ratio of 2.28 and a beta of 0.68. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $120.56. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a report on Wednesday, August 13th. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Morgan Stanley cut shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $59.00 to $47.00 in a report on Monday, September 29th. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Finally, Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.